Current Opinion in HIV and AIDS最新文献_第7页

Towards a molecular profile of antiretroviral therapy-free HIV remission. 对无抗逆转录病毒治疗的艾滋病毒缓解的分子概况。

IF 4.1 3区医学

Current Opinion in HIV and AIDS Pub Date : 2022-09-01 Epub Date: 2022-07-05 DOI: 10.1097/COH.0000000000000749

Philipp Adams, Ben Berkhout, Alexander O Pasternak

{"title":"Towards a molecular profile of antiretroviral therapy-free HIV remission.","authors":"Philipp Adams, Ben Berkhout, Alexander O Pasternak","doi":"10.1097/COH.0000000000000749","DOIUrl":"https://doi.org/10.1097/COH.0000000000000749","url":null,"abstract":"Purpose of review: To summarize the current status and highlight recent findings on predictive biomarkers for posttreatment HIV control (PTC) and virological remission. While historically, many studies focused on virological markers, there is an increasing tendency to enter immune and metabolic factors into the equation.Recent findings: On the virological side, several groups reported that cell-associated HIV RNA could predict time to viral rebound. Recent data hints at the possible importance of the genic location and chromatin context of the integrated provirus, although these factors still need to be assessed in relation to PTC and virological remission. Evidence from immunological studies highlighted innate and humoral immunity as important factors for prolonged HIV remission. Interestingly, novel metabolic markers have emerged, which offer additional angles to our understanding of latency and viral rebound.Summary: Facilitating PTC and virological remission remain top priorities for the HIV cure research. We advocate for clear and precise definitions for both phenomena in order to avoid misconceptions and to strengthen the conclusions that can be drawn. As no one-size-fits-all marker has emerged yet, more biomarkers are on the horizon, and viral rebound is a complex and heterogeneous process, it is likely that a combination of various biomarkers in cohesion will be necessary for a more accurate prediction of antiretroviral therapy-free HIV remission.","PeriodicalId":10949,"journal":{"name":"Current Opinion in HIV and AIDS","volume":" ","pages":"301-307"},"PeriodicalIF":4.1,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40689634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

HIV and cardiovascular disease: the role of inflammation. HIV与心血管疾病:炎症的作用。

IF 4.1 3区医学

Current Opinion in HIV and AIDS Pub Date : 2022-09-01 Epub Date: 2022-07-05 DOI: 10.1097/COH.0000000000000755

Sahera Dirajlal-Fargo, Nicholas Funderburg

{"title":"HIV and cardiovascular disease: the role of inflammation.","authors":"Sahera Dirajlal-Fargo, Nicholas Funderburg","doi":"10.1097/COH.0000000000000755","DOIUrl":"10.1097/COH.0000000000000755","url":null,"abstract":"Purpose of review: HIV and antiretroviral therapy (ART) use are linked to an increased incidence of atherosclerotic cardiovascular disease (ASCVD). Immune activation persists in ART-treated people with HIV (PWH), and markers of inflammation (i.e. IL-6, C-reactive protein) predict mortality in this population. This review discusses underlying mechanisms that likely contribute to inflammation and the development of ASCVD in PWH.Recent findings: Persistent inflammation contributes to accelerated ASCVD in HIV and several new insights into the underlying immunologic mechanisms of chronic inflammation in PWH have been made (e.g. clonal haematopoiesis, trained immunity, lipidomics). We will also highlight potential pro-inflammatory mechanisms that may differ in vulnerable populations, including women, minorities and children.Summary: Mechanistic studies into the drivers of chronic inflammation in PWH are ongoing and may aid in tailoring effective therapeutic strategies that can reduce ASCVD risk in this population. Focus should also include factors that lead to persistent disparities in HIV care and comorbidities, including sex as a biological factor and social determinants of health. It remains unclear whether ASCVD progression in HIV is driven by unique mediators (HIV itself, ART, immunodeficiency), or if it is an accelerated version of disease progression seen in the general population.","PeriodicalId":10949,"journal":{"name":"Current Opinion in HIV and AIDS","volume":"17 5","pages":"286-292"},"PeriodicalIF":4.1,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9370832/pdf/nihms-1818900.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10135804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

CD8 + T-cell responses in HIV controllers: potential implications for novel HIV remission strategies. HIV控制者的CD8 + t细胞反应:对新型HIV缓解策略的潜在影响

IF 4.1 3区医学

Current Opinion in HIV and AIDS Pub Date : 2022-09-01 DOI: 10.1097/COH.0000000000000748

Rachel L Rutishauser, Lydie Trautmann

{"title":"CD8 + T-cell responses in HIV controllers: potential implications for novel HIV remission strategies.","authors":"Rachel L Rutishauser, Lydie Trautmann","doi":"10.1097/COH.0000000000000748","DOIUrl":"https://doi.org/10.1097/COH.0000000000000748","url":null,"abstract":"Purpose of review: Immunological studies of spontaneous HIV and simian virus (SIV) controllers have identified virus-specific CD8 + T cells as a key immune mechanism of viral control. The purpose of this review is to consider how knowledge about the mechanisms that are associated with CD8 + T cell control of HIV/SIV in natural infection can be harnessed in HIV remission strategies.Recent findings: We discuss characteristics of CD8 + T-cell responses that may be critical for suppressing HIV replication in spontaneous controllers comprising HIV antigen recognition including specific human leukocyte antigen types, broadly cross-reactive T cell receptors and epitope targeting, enhanced expansion and antiviral functions, and localization of virus-specific T cells near sites of reservoir persistence. We also discuss the need to better understand the timing of CD8 + T-cell responses associated with viral control of HIV/SIV during acute infection and after treatment interruption as well as the mechanisms by which HIV/SIV-specific CD8 + T cells coordinate with other immune responses to achieve control.Summary: We propose implications as to how this knowledge from natural infection can be applied in the design and evaluation of CD8 + T-cell-based remission strategies and offer questions to consider as these strategies target distinct CD8 + T-cell-dependent mechanisms of viral control.","PeriodicalId":10949,"journal":{"name":"Current Opinion in HIV and AIDS","volume":"17 5","pages":"315-324"},"PeriodicalIF":4.1,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9378446/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9417022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 9

Cardiovascular disease risk in women living with HIV. 感染艾滋病毒的妇女患心血管疾病的风险。

IF 4.1 3区医学

Current Opinion in HIV and AIDS Pub Date : 2022-09-01 DOI: 10.1097/COH.0000000000000756

Katherine Kentoffio, Tecla M Temu, Saate S Shakil, Markella V Zanni, Chris T Longenecker

{"title":"Cardiovascular disease risk in women living with HIV.","authors":"Katherine Kentoffio, Tecla M Temu, Saate S Shakil, Markella V Zanni, Chris T Longenecker","doi":"10.1097/COH.0000000000000756","DOIUrl":"https://doi.org/10.1097/COH.0000000000000756","url":null,"abstract":"Purpose of review: To synthesize current evidence on the impact of cardiovascular disease among women living with HIV (WLWH) with a particular focus on disease prevalence, mechanisms and prevention.Recent findings: HIV-related cardiovascular disease risk is 1.5-fold to 2-fold higher for women than for men. Mechanisms of enhanced risk are multifactorial and include reinforcing pathways between traditional risk factors, metabolic dysregulation, early reproductive aging and chronic immune activation. These pathways influence both the presentation of overt syndromes of myocardial infarction, stroke and heart failure, as well as subclinical disease, such as microvascular dysfunction and cardiac fibrosis. Cardiovascular disease, therefore, remains a consistent threat to healthy aging among WLWH.Summary: Although no specific prevention strategies exist, patient-centered risk mitigation approaches that are adaptable to the needs of aging individuals are essential to combat disparities in cardiovascular outcomes among WLWH. Further research into the optimal prevention approach for CVD among WLWH, particularly for women living in under-resourced health systems, is needed.","PeriodicalId":10949,"journal":{"name":"Current Opinion in HIV and AIDS","volume":"17 5","pages":"270-278"},"PeriodicalIF":4.1,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9370828/pdf/nihms-1818902.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10189432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Prevention of heart failure, tachyarrhythmias and sudden cardiac death in HIV. 预防艾滋病毒感染者的心力衰竭、快速性心律失常和心脏性猝死。

IF 4.5 3区医学

Current Opinion in HIV and AIDS Pub Date : 2022-09-01 Epub Date: 2022-07-16 DOI: 10.1097/COH.0000000000000753

Katherine C Wu, Bethel Woldu, Wendy S Post, Allison G Hays

{"title":"Prevention of heart failure, tachyarrhythmias and sudden cardiac death in HIV.","authors":"Katherine C Wu, Bethel Woldu, Wendy S Post, Allison G Hays","doi":"10.1097/COH.0000000000000753","DOIUrl":"10.1097/COH.0000000000000753","url":null,"abstract":"Purpose of review: To summarize the state-of-the-art literature on the epidemiology, disease progression, and mediators of heart failure, tachyarrhythmias, and sudden cardiac death in people living with HIV (PLWH) to inform prevention strategies.Recent findings: Recent studies corroborate the role of HIV as a risk enhancer for heart failure and arrhythmias, which persists despite adjustment for cardiovascular risk factors and unhealthy behaviors. Immune activation and inflammation contribute to the risk. Heart failure occurs more frequently at younger ages, and among women and ethnic minorities living with HIV, highlighting disparities. Prospective outcome studies remain sparse in PLWH limiting prevention approaches. However, subclinical cardiac and electrophysiologic remodeling and dysfunction detected by noninvasive testing are powerful disease surrogates that inform our mechanistic understanding of HIV-associated cardiovascular disease and offer opportunities for early diagnosis.Summary: Aggressive control of HIV viremia and cardiac risk factors and abstinence from unhealthy behaviors remain treatment pillars to prevent heart failure and arrhythmic complications. The excess risk among PLWH warrants heightened vigilance for heart failure and arrhythmic symptomatology and earlier testing as subclinical abnormalities are common. Future research needs include identifying novel therapeutic targets to prevent heart failure and arrhythmias and testing of interventions in diverse groups of PLWH.","PeriodicalId":10949,"journal":{"name":"Current Opinion in HIV and AIDS","volume":"17 5","pages":"261-269"},"PeriodicalIF":4.5,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365326/pdf/nihms-1818903.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10189430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Addressing gaps in cardiovascular care for people with HIV: bridging scientific evidence and practice. 解决艾滋病毒感染者心血管护理方面的差距:衔接科学证据和实践。

IF 4.1 3区医学

Current Opinion in HIV and AIDS Pub Date : 2022-09-01 DOI: 10.1097/COH.0000000000000754

Albert Liu, Matthew Feinstein

{"title":"Addressing gaps in cardiovascular care for people with HIV: bridging scientific evidence and practice.","authors":"Albert Liu, Matthew Feinstein","doi":"10.1097/COH.0000000000000754","DOIUrl":"https://doi.org/10.1097/COH.0000000000000754","url":null,"abstract":"Purpose of review: People with HIV continue to have an excess burden of cardiovascular disease compared to the general population. The reasons for these disparities in cardiovascular disease include HIV-specific risk enhancers, traditional atherosclerotic cardiovascular disease risk factors, and sociodemographic disparities, all of which are ripe targets for intervention.Recent findings: Accurate risk prediction of atherosclerotic cardiovascular disease remains difficult, and cardiovascular risk for people with HIV may be underestimated in the absence of HIV-specific risk enhancers. Despite this increased cardiovascular risk, people with HIV are undertreated and often placed on inadequate lipid lowering therapy. Structural racism and HIV-related stigma play a role, and provider-level and structural-level interventions to encourage early identification and treatment of persons at high risk are necessary.Summary: Persons with HIV should be screened with existing cardiovascular risk prediction tools, and those at high risk cardiovascular disease should be promptly referred for lifestyle and pharmacologic interventions as appropriate. System-level implementation research is ongoing in attempts to narrow the gap in cardiovascular care, particularly for vulnerable communities in low resource settings.","PeriodicalId":10949,"journal":{"name":"Current Opinion in HIV and AIDS","volume":"17 5","pages":"279-285"},"PeriodicalIF":4.1,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9373406/pdf/nihms-1818901.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10487360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The future of long-acting agents for preexposure prophylaxis. 暴露前预防长效药物的未来。

IF 4.1 3区医学

Current Opinion in HIV and AIDS Pub Date : 2022-07-01 DOI: 10.1097/COH.0000000000000735

Charles Flexner

{"title":"The future of long-acting agents for preexposure prophylaxis.","authors":"Charles Flexner","doi":"10.1097/COH.0000000000000735","DOIUrl":"https://doi.org/10.1097/COH.0000000000000735","url":null,"abstract":"Purpose of review: The main reason for the failure of oral preexposure prophylaxis (PrEP) regimens for HIV is poor adherence. Intramuscular cabotegravir was recently approved for PrEP, and a number of other long-acting antiretroviral formulations and products are currently in clinical development. This includes subcutaneous and intravenous injections, implants, and microarray (microneedle) patches, as well as extended duration oral drugs. The success and future uptake of these products will depend on a variety of factors.Recent findings: Long-acting delivery of antiretroviral agents for PrEP confers significant advantages over short-acting oral delivery. This is exemplified by the superior efficacy of intramuscular cabotegravir given every eight weeks as compared to daily oral co-formulated tenofovir disoproxil fumarate and emtricitabine. There is also evidence for PrEP efficacy for a broadly neutralizing monoclonal antibody given intravenously every eight weeks. One of the leading candidates for long-acting PrEP, islatravir, was being studied as a monthly oral drug or a nonerodable subcutaneous implant inserted for up to 12 months. However, clinical studies of this agent were put on hold in late 2021 because of unanticipated lymphopenia.Summary: Long-acting antiretroviral products have substantial promise for PrEP and have particular advantages over daily oral drugs based mainly on improved adherence. However, there are barriers to further uptake that include the need for more intensive interaction with systems of healthcare delivery, greater expense and complexity of implementation, and unexpected long-term toxicities.","PeriodicalId":10949,"journal":{"name":"Current Opinion in HIV and AIDS","volume":"17 4","pages":"192-198"},"PeriodicalIF":4.1,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9467455/pdf/nihms-1785297.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10194701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

HIV drug resistance in various body compartments. 不同身体部位的HIV耐药性。

IF 4.1 3区医学

Current Opinion in HIV and AIDS Pub Date : 2022-07-01 DOI: 10.1097/COH.0000000000000741

Gert U van Zyl, Jeffrey R Dorfman, Mary F Kearney

{"title":"HIV drug resistance in various body compartments.","authors":"Gert U van Zyl, Jeffrey R Dorfman, Mary F Kearney","doi":"10.1097/COH.0000000000000741","DOIUrl":"https://doi.org/10.1097/COH.0000000000000741","url":null,"abstract":"Purpose of review: HIV drug resistance testing using blood plasma or dried blood spots forms part of international guidelines. However, as the clinical utility of assessing drug resistance in other body compartments is less well established, we review this for blood cells and samples from other body compartments.Recent evidence: Although clinical benefit is not clear, drug resistance testing in blood cells is often performed when patients with suppressed plasma viral loads require a treatment substitution. In patients with HIV neurocognitive disease, cerebral spinal fluid (CSF) drug resistance is rarely discordant with plasma but has nevertheless been used to guide antiretroviral drug substitutions. Cases with HIV drug resistance in genital fluids have been documented but this does not appear to indicate transmission risk when blood plasma viral loads are suppressed.Summary: Drug-resistant variants, which may be selected in tissues under conditions of variable adherence and drug penetration, appear to disseminate quickly, and become detectable in blood. This may explain why drug resistance discordance between plasma and these compartments is rarely found. Partial compartmentalization of HIV populations is well established for the CSF and the genital tract but other than blood plasma, evidence is lacking to support drug resistance testing in body compartments.","PeriodicalId":10949,"journal":{"name":"Current Opinion in HIV and AIDS","volume":" ","pages":"205-212"},"PeriodicalIF":4.1,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40406117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Epidemiology of HIV drug resistance in low- and middle-income countries and WHO global strategy to monitor its emergence. 低收入和中等收入国家艾滋病毒耐药性流行病学和世卫组织监测其出现的全球战略。

IF 4.5 3区医学

Current Opinion in HIV and AIDS Pub Date : 2022-07-01 DOI: 10.1097/COH.0000000000000743

Silvia Bertagnolio, Michael R Jordan, Amalia Giron, Seth Inzaule

{"title":"Epidemiology of HIV drug resistance in low- and middle-income countries and WHO global strategy to monitor its emergence.","authors":"Silvia Bertagnolio, Michael R Jordan, Amalia Giron, Seth Inzaule","doi":"10.1097/COH.0000000000000743","DOIUrl":"10.1097/COH.0000000000000743","url":null,"abstract":"Purpose of review: This review summarises the latest information of the epidemiology of HIV drug resistance (HIVDR) in low- and middle-income countries and the updated WHO global strategy for HIVDR surveillance and monitoring.Recent findings: Finding from recent national-representative surveys show a rise in pretreatment drug resistance (PDR) to reverse transcriptase inhibitors and especially to the class of nonnucleoside reverse transcriptase inhibitors. Levels of PDR are especially high in infants <18 months and adults reporting prior exposure to antiretrovirals. Although viral suppression rates are generally high and increasing among adults on antiretroviral therapy, those with unsuppressed viremia have high levels of acquired drug resistance (ADR). Programmatic data on HIVDR to integrase-transfer-inhibitor resistance is scarce, highlighting the need to increase integrase-inhibitors resistance surveillance. As the landscape of HIV prevention, treatment and monitoring evolves, WHO has also adapted its strategy to effectively support countries in preventing and monitoring the emergence of HIVDR. This includes new survey methods for monitoring resistance emerging from patients diagnosed with HIV while on preexposure prophylaxis, and a laboratory-based ADR survey leveraging on remnant viral load specimens which are expected to strengthen dolutegravir-resistance surveillance.Summary: Monitoring HIVDR remains pivotal to ensure countries attain and sustain the global goals for ending HIV as a public health threat by 2030.","PeriodicalId":10949,"journal":{"name":"Current Opinion in HIV and AIDS","volume":" ","pages":"229-239"},"PeriodicalIF":4.5,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40406119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How could HIV-1 drug resistance impact preexposure prophylaxis for HIV prevention? HIV-1耐药性如何影响HIV预防的暴露前预防?

IF 4.1 3区医学

Current Opinion in HIV and AIDS Pub Date : 2022-07-01 DOI: 10.1097/COH.0000000000000746

Urvi M Parikh, John W Mellors

{"title":"How could HIV-1 drug resistance impact preexposure prophylaxis for HIV prevention?","authors":"Urvi M Parikh, John W Mellors","doi":"10.1097/COH.0000000000000746","DOIUrl":"https://doi.org/10.1097/COH.0000000000000746","url":null,"abstract":"Purpose of review: To review current laboratory and clinical data on the frequency and relative risk of drug resistance and range of mutations selected from approved and investigational antiretroviral agents used for preexposure prophylaxis (PrEP) of HIV-1 infection, including tenofovir disproxil fumarate (TDF)-based oral PrEP, dapivirine ring, injectable cabotegravir (CAB), islatravir, lenacapavir and broadly neutralizing antibodies (bNAbs).Recent findings: The greatest risk of HIV-1 resistance from PrEP with oral TDF/emtricitabine (FTC) or injectable CAB is from starting or continuing PrEP after undiagnosed acute HIV infection. By contrast, the dapivirine intravaginal ring does not appear to select nonnucleoside reverse transcriptase inhibitor resistance in clinical trial settings. Investigational inhibitors including islatravir, lenacapavir, and bNAbs are promising for use as PrEP due to their potential for sustained delivery and low risk of cross-resistance to currently used antiretrovirals, but surveillance for emergence of resistance mutations in more HIV-1 gene regions (gag, env) will be important as the same drugs are being developed for HIV therapy.Summary: PrEP is highly effective in preventing HIV infection. Although HIV drug resistance from PrEP use could impact future options in individuals who seroconvert on PrEP, the current risk is low and continued monitoring for the emergence of resistance and cross-resistance during product development, clinical studies, and product roll-out is advised to preserve antiretroviral efficacy for both treatment and prevention.","PeriodicalId":10949,"journal":{"name":"Current Opinion in HIV and AIDS","volume":"17 4","pages":"213-221"},"PeriodicalIF":4.1,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245149/pdf/nihms-1798028.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10194702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3